Abstract
The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
Original language | English |
---|---|
Number of pages | 4 |
Journal | Nature Medicine |
Early online date | 19 Apr 2024 |
DOIs |
|
Publication status | E-pub ahead of print - 19 Apr 2024 |
Keywords
- Drug regulation
- Health policy
- Non-alcoholic fatty liver disease
- Non-alcoholic steatohepatitis
- Public health
ASJC Scopus subject areas
- General Biochemistry,Genetics and Molecular Biology